Similar articles

• Type 2 diabetes in pregnancy: a wolf in sheep's clothing.

  Cheung NW, McElduff A, Ross GP. Cheung NW, et al. Aust N Z J Obstet Gynaecol. 2005 Dec;45(6):479-83. doi: 10.1111/j.1479-828X.2005.00480.x. Aust N Z J Obstet Gynaecol. 2005. PMID: 16401211 Review.
• Sulfonylurea therapy is associated with increased NT-proBNP levels in the treatment of type 2 diabetes.

  Tildesley HD, Aydin CM, Ignaszewski A, Strelzow JA, Yu E, Bondy G. Tildesley HD, et al. Int J Cardiol. 2007 Feb 14;115(3):312-7. doi: 10.1016/j.ijcard.2006.03.014. Epub 2006 Jul 7. Int J Cardiol. 2007. PMID: 16824633
• Angiotensin II receptor antagonist in pregnancy.

  Chow KM, Lam CM. Chow KM, et al. J Perinatol. 2004 Jan;24(1):56-7; author reply 57. doi: 10.1038/sj.jp.7211011. J Perinatol. 2004. PMID: 14726941 No abstract available.
• [Pharmacodynamics of second-generation sulfonylureas: dose-effect curve of gliquidone in type II diabetics].

  Procacci V, Giovine A, Roberto MG, Ronchi AM, Lasorsa G, Vendemiale G, Stufano N, Altomare E. Procacci V, et al. Boll Soc Ital Biol Sper. 1988 Aug;64(8):731-8. Boll Soc Ital Biol Sper. 1988. PMID: 3214573 Italian. No abstract available.
• Diabetic management in high risk patients (pregnancy, insulin pumps).

  Vanhaverbeke G, Mertens A, Mathieu C. Vanhaverbeke G, et al. Acta Clin Belg. 2004 Jul-Aug;59(4):173-81. doi: 10.1179/acb.2004.026. Acta Clin Belg. 2004. PMID: 15597723 Review.